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Background and purpose: To analyze the long-term risk of second primary solid non-breast cancer in a
national population-based cohort of 46,176 patients treated for early breast cancer between 1982 and
2007.
Patients and methods: All patients studied were treated according to the national guidelines of the Danish
Breast Cancer Cooperative Group. The risk of second primary cancers was estimated by Standardised inci-
dence ratios (SIRs) and multivariate Cox regression models were used to estimate adjusted hazard ratios
(HR) among irradiated women compared to non-irradiated. All irradiated patients were treated on linear
accelerators. Second cancers were a priori categorized into two groups; radiotherapy-associated-
(oesophagus, lung, heart/mediastinum, pleura, bones, and connective tissue) and non-radiotherapy-asso-
ciated sites (all other cancers).
Results: 2358 second cancers had occurred during the follow-up. For the radiotherapy-associated sites
the HR among irradiated women was 1.34 (95% CI 1.11–1.61) with signiﬁcantly increased HRs for the
time periods of 10–14 years (HR 1.55; 95% CI 1.08–2.24) and P15 years after treatment (HR 1.79; 95%
CI 1.14–2.81). There was no increased risk for the non-radiotherapy-associated sites (HR 1.04; 95% CI
0.94–1.1). The estimated attributable risk related to radiotherapy for the radiotherapy-associated sites
translates into one radiation-induced second cancer in every 200 women treated with radiotherapy.
Conclusions: Radiotherapy treated breast cancer patients have a small but signiﬁcantly excess risk of sec-
ond cancers.
 2013 Elsevier Ireland Ltd. Open access under CC BY-NC-ND license.
Radiotherapy and Oncology 106 (2013) 42–49Breast cancer is the most frequent cancer among European wo-
men [1]. The use of postoperative radiotherapy in early breast can-
cer treatment has increased over the last 20 years and has been
shown to decrease loco-regional recurrence rates and to improve
survival [2–5]. With the recent advances in treatment the progno-
sis of breast cancer is generally favorable and a growing number of
women are becoming long-term survivors [1,6]. These women are
at risk of developing radiotherapy-induced second malignancy [7].
Several epidemiological studies and one overview analysis have
reported increased risks of second primary malignancies among
breast cancer patients treated with postoperative radiotherapy
[3,8–13]. However, many of these previous studies, included pa-
tients treated with a variety of radiotherapy techniques and dos-
ages that are obsolete today.oral presentation at: ESTRO
perimental Clinical Oncology,
lding 5, Dk-8000 Århus C,
u).
er CC BY-NC-ND license.As part of the ALLEGRO EURATOM project [14] the aim of this
study is to evaluate the occurrence of second primary solid non-
breast cancer among Danish women treated for early breast cancer
with postoperative radiotherapy reﬂecting contemporary stan-
dards in radiation. The incidence of second primary cancer among
women treated with radiotherapy was compared to both the gen-
eral Danish female population and to those who were non-
irradiated.
Patients and methods
Data were supplied by the Danish Breast Cancer Cooperative
Group (DBCG); established in 1977 to ensure uniform national
diagnostic and therapeutic breast cancer guidelines. Since then wo-
men in Denmark diagnosed with primary, unilateral loco-regional
breast cancer are included in a nationwide clinical database under
the DBCG containing information regarding tumor characteristics
and patient follow-up. Treatment interventions including surgery,
systemic treatment and radiotherapy are recorded for patients trea-
ted according to DBCG guidelines. All information is reported on
standardized forms by the departments involved with diagnosis
T. Grantzau et al. / Radiotherapy and Oncology 106 (2013) 42–49 43and treatment. Vital status is updated annually by linkage to the
Danish Civil Registration System [15].
The study-cohort included all women in Denmark aged
20 years or older, diagnosed with histologically conﬁrmed ﬁrst
primary invasive loco-regional breast cancer and treated accord-
ing to the 1982–2007 DBCG guidelines (Fig. 1). Only one-year sur-
vivors were included to eliminate the possibility of concomitant
cancer diagnoses. To attain risk estimates for second cancers
reﬂecting current practice in radiotherapy, we excluded 132 wo-
men treated with orthovoltage X-ray. All irradiated women had
thus been treated on linear accelerators. The ﬁnal cohort included
46,176 women.
The cohort was divided into two groups according to whether
the patients had been prescribed postoperative radiotherapy or
not. The DBCG recommendations regarding the indications for
radiotherapy have changed somewhat over time however the
treatment techniques and dosages have changed little [15,16].
The majority of patients allocated to post-mastectomy irradiation
were treated with a combined 3-ﬁeld anterior electron/photon
technique consisting of an electron ﬁeld to the chest wall ± the
internal mammary chain combined with photon ﬁelds against
the lateral thorax and supraclavicular fossa. The median absorbed
dose in the target volume was 48–50 Gy, given in 24–25 fractions
over 5 weeks [16]. All patients treated with breast conserving sur-
gery (BCS) received postoperative radiotherapy against the resid-
ual breast. The majority of patients were treated with tangential
photon ﬁelds of the conserved breast combined with a boost to
the tumor bed, primarily with electrons. The median absorbed
dose in the target volume was 48–50 Gy, given in 24–25 fractionsPatients treated according to
1982-2007 DBCG guidelines
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Fig. 1. Flowchart. 1DBCG: The Danishover 4 12—5 weeks followed by a boost to the tumor bed of 10–
24 Gy over 5–12 fractions [16]. Risks were not estimated according
to whether patients had been treated with a mastectomy or BCS as
the differences between radiotherapy techniques were small. Fur-
ther, women were mainly treated with BCS after 1996 thereby con-
tributing with fewer follow-up years.
Second primary cancers were identiﬁed by linking the cohort to
the national Danish Cancer Registry. Since 1943, all incident cases
of cancer in Denmark have been reported to the Registry on notiﬁ-
cation forms from all clinical departments and departments of
pathology and forensic medicine, supplemented with information
from death certiﬁcates. Beginning in 2004, the Cancer Registry
has utilized electronic reporting from other health registries. Tu-
mors diagnosed since 1978 have been classiﬁed according to the
International Classiﬁcation of Disease, 10th revision (ICD-10) and
the International Classiﬁcation of Diseases for Oncology, third edi-
tion (ICD-O-3). Reports from multiple sources and quality control
routines secure a high degree of completeness and validity of the
Registry [17].
All types of second solid cancers except non-melanoma skin-,
ill-deﬁned- and second-breast-cancers were included as an out-
come. Second primary breast cancers were not included since only
the ﬁrst primary breast cancer has been entered in the computer-
ized version of the Registry for bilateral breast cancers with iden-
tical histology. Women were censored from analysis at date of
recurrence or diagnosis of a contra-lateral breast cancer, if this
was the ﬁrst event during clinical follow-up. Further, only the ﬁrst
second primary cancer was counted to avoid inﬂuence from other
treatments given for subsequent cancers.atients treated with orthovoltage radiotherapy
tients diagnosed with a second primary < 1 
ar after the primary breast cancer diagnosis 
tients diagnosed with a recurrence of breast 
ncer < 1 year after the primary breast cancer 
agnosis 
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Breast Cancer Cooperative Group.
44 Second cancer after radiotherapy in breast cancer patientsThe second cancers were a priori classiﬁed into two subgroups:
(1) sites potentially associated with radiation exposure (RT-
associated); and (2) sites not associated with radiation exposure
(non-RT-associated). This grouping of cancer sites was based on
considerations of how close the anatomical relation was to the
treatment ﬁeld and on a review of the literature. Previous studies
have shown an increased risk of cancer in the oesophagus
[8,9,12,13,18], lung [3,8,10,12,19] aswell as bone and soft tissue sar-
comas [3,8,10, 19–21]. These cancer sites, alongwith pleura, and the
heart/mediastinum, were thus categorized as RT-associated sites.
The follow-up for each patient began one year after the initial
breast cancer diagnosis (1983–2008) and ended on the date of
the second primary malignancy, recurrence of breast cancer, date
of death, date of emigration or end of follow up (December 31,
2008), whichever occurred ﬁrst.
Statistical methods
Standardised incidence ratios (SIR) for second primary cancer
were calculated as the observed number of cancer cases divided
by the expected number. The expected number of cancers was
computed from accumulated person-years at risk and primaryTable 1
Descriptive characteristics of 46,176 one-year survivors diagnosed with early breast cancer
with DBCG guidelines for the period 1982–2007.
Characteristics Irradiated
n %a
All women 23,627 100
Age at breast cancer diagnosis
20–39 1,816 8
40–49 5,934 25
50–59 7,708 33
60–69 6,443 27
P70 1,726 7
Year of breast cancer diagnosis
1982–1986 971 4
1987–1991 1,902 8
1992–1996 3,413 15
1997–2001 5,716 24
2002–2006 9,296 39
2007 2,329 10
Systemic treatment
Noneb 6,590 28
Chemotherapy 5,545 23
Endocrine therapyc 7,873 33
Chemotherapy + endocrine therapy 3,619 15
Surgery
Mastectomy 9,039 38
Breast conserving operation (BCS) 14,588 62
PY at risk by latencyd
1–4 years 68,678 53
5–9 years 39,034 30
10–14 years 15,780 12
> 15 years 7,273 6
Subtotal 130,765 101
Median follow-up in years 5
Range (1–26)
Median age at breast cancer diagnosis 55
Range (21–93)
Median age at second cancer diagnosis 64
Range (30–87)
Median latency in years 6
Range (1–24)
a Percentages may not sum to 100 because of rounding.
b Includes 560 patients treated with ovarian castration among the irradiated women
c Includes 38 patients treated with ovarian castration among the irradiated women a
d Person years at risk by latency from breast cancer diagnosis to second primary canccancer incidence rates of the general Danish female population in
ﬁve-year age-groups and ﬁve-year calendar-periods. Conﬁdence
intervals (95% CI) were estimated assuming that the expected
cases were Poisson distributed.
A direct comparison of cancer incidence in the radiotherapy
group with that in the non-radiotherapy group was performed in
multivariate Cox regression analyses with the estimation of hazard
ratios (HR) for second primary cancers stratifying for age and
adjusting for chemotherapy, endocrine-therapy and calendar-year
at breast cancer diagnosis. HR’s were estimated for all one-year
survivors and in ﬁve-year intervals since breast cancer treatment.
We further evaluated the possible interaction between radiother-
apy and treatment with chemotherapy, endocrine therapy or a
combination of the two. All risks were calculated relative to pa-
tients who were non-irradiated. All p-values are two-sided with
a level of signiﬁcance at 5%.
The number of excess cancers related to radiotherapy was cal-
culated as described by Berrington de GA et al. [8]. The number
of second cancers among the irradiated women was subtracted
from the number of second cancers that would have occurred
among the women if they had not been treated with radiotherapy;
i.e. calculated as the observed number of cancers divided by the, according to whether they received postoperative radiotherapy or not, in agreement
Non-irradiated Probability of Student t-test
n %
22,549 100
<.001
1,100 5
4,300 19
6,631 29
7,247 32
3,271 15
<.001
3,505 15
4,679 21
5,766 26
4,677 21
3,223 14
699 3
<.001
11,676 52
3,393 15
5,980 27
1,500 7
<.001
22,548 99
1 <1
71,902 39
57,926 32
33,001 18
20,661 11
183,490 100
8
(1–26)
58
(21–96)
69
(35–98)
7
(1–25)
and 193 patients among the non-irradiated.
nd 7 patients among the non-irradiated.
er diagnosis.
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was estimated by dividing the number of excess cancers with the
total number of cancer cases. The excess absolute risk (EAR) related
to radiotherapy was calculated as the number of excess cancers
associated to radiotherapy divided by the person-years at risk
and then multiplied by 10,000. The analyses were performed using
SAS and Stata lC 11.2.
Results
The study cohort included a total of 46,176 patients. Overall,
51% of the women received postoperative radiotherapy while
49% did not (Table 1). Irradiated women were younger at breast
cancer diagnosis and more frequently treated with chemotherapy
and endocrine therapy compared to non-irradiated women.
Table 2 shows the observed and expected number of second
cancers compared to the general female population and Fig. 2 the
adjusted HR of second primary cancers comparing irradiated wo-
men with non-irradiated. A total of 2358 second primary cancers
developed during the follow-up period. Among the irradiated wo-
men 928 second primary cancers develop, whereas 784 cancers
were expected (SIR 1.18; 95% CI 1.11–1.26) (Table 2). 1430 second
primary cancers were observed among the non-irradiated women,Table 2
Observed (Obs) and expected (Exp) numbers of second non-breast cancers with correspondi
in Denmark treated or untreated with radiation according to DBCG 1982–2007 guidelines
Second primary cancer sitea Irradiated
Obs Expected SIR
RT-associated sitesc
Oesophagus 15 9.30 1.61
Lung, bronchus and trachea 186 173.37 1.07
Heart and mediastinum 3 0.92 3.26
Pleura 4 1.44 2.78
Bones, joints and articular cartilage 2 1.01 1.99
Connective tissue 16d 5.18 3.09
Subtotal RT-associated sites 226 191.33 1.18
All non-RT-associated sites
Salivary glands 2 1.86 1.07
Thyroid gland 9 7.18 1.25
Buccal cavity and pharynx 21 18.25 1.15
Larynx 7 4.84 1.45
Stomach 20 15.95 1.25
Small intestine 1 3.22 0.31
Colon incl- rectosigmoideum 118 106.52 1.11
Liver, gallbladder and biliary tract 10 16.13 0.62
Pancreas 43 35.55 1.21
Peritoneum and retroperitoneum 4 2.04 1.96
Rectum and anus 56 51.25 1.09
Melanoma of skin 50 47.80 1.05
Urinary tract 65 62.81 1.03
Corpus uteri 98 71.09 1.38
Ovary, fallopian tube and broad ligament 91 56.98 1.60
Other female genital 31 36.17 0.86
Brain and nervous system 75 51.67 1.45
Other sites 1f 4.36 0.92
Subtotal non-RT-associated sites 702 590.75 1.19
Total all sites 928 783.99 1.18
a Only solid second primary non-breast cancers were included. Furthermore, cancers o
10 = C44) were excluded.
b 95% Conﬁdence intervals.
c Radiotherapy-associated sites: oesophagus, lung, heart/mediastinum, pleura, bones,
d Anatomical location: thorax (Obs = 10), upper arm (Obs = 2), abdomen (Obs = 2), lowe
malignant ﬁbrous histocytomas (MFH), 2 leiomyosarcoma, 1 liposarcoma and 5 others.
e Anatomical location: thorax (Obs = 5), lower limp (Obs = 4) and abdomen (Obs =
ﬁbrosarcoma, 2 liposarcoma, 1 leiomyosarcoma and 3 others.
f Includes: 1 other cancer of the endocrine glands.
g Includes: 1 unspeciﬁed cancer of the digestive organs, 3 cancers of the nasal cavitiewhereas 1350 cancers were expected (SIR 1.06; 95% CI 1.01–1.12).
The adjusted HR for all second primary was 1.10 (95% CI 1.01–1.21,
p = 0.03) (Fig. 2).
For the second cancer classiﬁed as RT-associated a signiﬁcantly
elevated SIR was found among irradiated women based on 226
second cancers (SIR 1.18, 95% CI 1.03–1.35), while the SIR among
the non-irradiated women was close to unity, based on 328 second
cancers (SIR 1.02; 95% CI 0.91–1.14). The adjusted HR for the RT-
associated sites was 1.34 (95% CI 1.11–1.61, p = 0.002). HR’s for
the individual sites in this group contributing with most cases
was calculated and was signiﬁcantly increased for lung cancer
(HR 1.27; 95% CI 1.04–1.55) and connective tissue (HR 2.96; 95%
CI 1.17–6.18) but not signiﬁcantly increased for oesophageal can-
cer HR 1.17 (95% CI 0.56–2.44).
For the cancer sites classiﬁed as non-RT-associated, SIRs were
increased among both radiotherapy-treated (SIR 1.19; 95% CI
1.10–1.28) and non-treated patients (SIR 1.07; 95% CI 1.01–1.14),
but there was no excess risk associated with radiotherapy HR
1.04 (95% CI 0.94–1.16). Radiotherapy-treated women had signiﬁ-
cantly elevated SIRs for ovarian and corpus uteri cancer but when
comparing irradiated women with non-irradiated there was no in-
creased risk associated with radiotherapy for both ovarian (HR
1.11; 95% CI 0.82–1.51) and corpus uteri cancer (HR 0.93; 95% CIng Standardised incidence ratios (SIR) among one-year survivors of early breast cancer
.
Non-irradiated
95% CIb Obs Expected SIR 95% CI
0.90–2.66 20 16.67 1.20 0.73–1.85
0.92–1.24 292 291.31 1.00 0.89–1.12
0.66–9.53 1 1.62 0.62 0.01–3.44
0.75–7.11 3 2.64 1.14 0.23–3.32
0.22–7.18 1 1.68 0.59 0.01–3.30
1.77–5.02 IIe 8.00 1.38 0.69–2.46
1.03–1.35 328 321.92 1.02 0.91–1.14
0.12–3.88 2 3.21 0.62 0.07–2.25
0.57–2.38 11 9.51 1.16 0.58–2.07
0.71–1.76 41 27.87 1.47 1.06–2.00
0.58–2.98 5 8.17 0.61 0.20–1.43
0.77–1.94 42 30.35 1.38 1.00–1.87
0.00–1.73 11 5.28 2.08 1.04–3.72
0.92–1.33 193 204.68 0.94 0.81–1.09
0.30–1.14 32 32.79 0.98 0.67–1.38
0.88–1.63 70 64.77 1.08 0.84–1.37
0.53–5.01 5 3.27 1.53 0.49–3.57
0.83–1.42 109 90.08 1.21 0.99–1.46
0.78–1.38 78 67.34 1.16 0.92–1.45
0.80–1.32 113 116.54 0.97 0.80–1.17
1.12–1.68 155 122.10 1.27 1.08–1.49
1.29–1.96 113 96.37 1.17 0.97–1.41
0.58–1.22 50 61.28 0.82 0.61–1.08
1.14–1.82 67 78.00 0.86 0.67–1.09
0.25–2.35 5g 8.01 0.75 0.28–1.63
1.10–1.28 1102 1028.00 1.07 1.01–1.14
1.11–1.26 1430 1349.89 1.06 1.01–1.12
f ill-deﬁned nature (ICD-10 = C76 - C80) as well as non-melanoma skin cancer (ICD-
articular cartilage and connective tissue.
r limp (Obs = l), and unknown location (Obs = l). Histopathology: 5 angiosarcomas, 3
2). Histopathology: 1 angiosarcoma, 3 malignant ﬁbrous histocytomas (MFH), 1
s, middle ear and sinuses and 1 other cancer of the endocrine glands.
Fig. 2. Hazard ratios of second primary cancers among 46,176 one-year survivors of early breast cancer comparing irradiated women with non-irradiated. 1Only solid second
primary non-breast cancers were included. 2Hazard ratios with corresponding 95% Conﬁdence intervals. HR’s were adjusted for age at breast cancer diagnosis, year of breast
cancer diagnosis, chemotherapy and endocrine therapy. 3RT-associated sites: oesophagus, lung, heart/mediastinum, pleura, bones, articular cartilage and connective tissue.
46 Second cancer after radiotherapy in breast cancer patients0.71–1.23). A signiﬁcantly increased incidence of CNS cancer was
observed among irradiated women compared with both the gen-
eral female population and with non-irradiated women. In both
cases though, the risk was only signiﬁcantly increased 1–4 years
after treatment (SIR 1.58; 95% CI 1.13–2.16) and (HR 2.51; 95% CI
1.39–4.56).
Risks of second cancer according to the systemic treatment
given for breast cancer were calculated for all second cancers,
the RT-associated- and non-RT-associated-sites (Supplementary
Table 1). All risks were calculated relative to patients who were
non-irradiated and treated either with no systemic treatment,
chemotherapy and/or endocrine therapy. The addition of chemo-
therapy together with radiation gave a higher HR than that seen
for ’RT only’, but these HRs were not signiﬁcantly different
(p = 0.40).Hazard ratios by time since breast cancer treatment comparing
irradiated patients with non-irradiated are shown in Fig. 3. For
the RT-associated sites the risk increasedwith time since treatment
and was signiﬁcantly greater than one for the time periods 10–14
(HR 1.55; 95% CI 1.08–2.24) and 15 or more years after treatment
(HR 1.79; 95% CI 1.14–2.81). As lung cancer contributed 86% of
the second cancers in this category, HRs for the RT-associated sites
excluding lung cancer were estimated. The risk was signiﬁcantly in-
creased for the time period 10–14 years after treatment (HR 2.74;
95% CI 1.05–7.15). At 15 or more years after treatment there was
no increased risk but the estimated is based on a few cases. No in-
creased risk over time was observed for the combined group of sec-
ond cancers classiﬁed as non-RT-associated. HRs according to time
since treatment was also calculated for the non-RT-associated sites.
A HR speciﬁcally for the transverse colon and the ﬂexures (n = 45),
Fig. 3. Hazard ratios of second primary cancers by time since treatment among 46,176 one-year survivors of early breast cancer comparing irradiated women with non-
irradiated. 1Only solid second primary non-breast cancers were included. 2Person years at risk. 3Hazard ratios with corresponding 95% Conﬁdence intervals. HR’s were
adjusted for age at breast cancer diagnosis, year of breast cancer diagnosis, chemotherapy and endocrine therapy. 4RT-associated sites: oesophagus, lung, heart/mediastinum,
pleura, bones, articular cartilage and connective tissue.
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ever, none of these sites showed a latency-pattern resembling that
of the RT-associated sites (data not shown).
Among the irradiated women the attributable risk related to
radiotherapy was 9% for all second solid cancers and the corre-
sponding excess absolute risk was 6 cases per 10,000 person-years
(Table 3). For the RT-associated sites the attributable risk related to
radiotherapy was 25% and the corresponding excess absolute risk
was 4 cases per 10,000 person-years.
Discussion
In this nation-wide study of over 46,000 patients of early breast
cancer, we found a signiﬁcantly increased risk for the combinedgroup of second primary cancers a priori classiﬁed as RT-associated
among radiotherapy treated women compared to non-treated wo-
men. The risk increased over time and was signiﬁcantly elevated
10 or more years after treatment. For all other sites combined,
there was no signiﬁcantly increased risk among irradiated women
compared to non-irradiated.
The strength of this study is its national-, population-, and reg-
istry-based nature covering up to 26 years of follow-up. None of
the cohort members were lost to follow-up, and second primary
cancers were ascertained independently of radiotherapy status.
Only the ﬁrst second primary cancer was included in the analysis
and the date of breast cancer recurrence during follow-up was a
censoring date, eliminating the inﬂuence from subsequent cancer
treatments. We adjusted the analysis for chemotherapy and endo-
Table 3
Excess cancers, attributable risk percent and excess absolute risk (EAR) per 10,000 person years (PY) related to radiotherapy among one-year survivors for all second non-breast
cancer sites and radiotherapy-associated sites. EAR per 10,000 person years in comparison with the general Danish female population among one-year survivors treated and not
treated with radiotherapy.
Irradiated Non-irradiated
Related to radiotherapy
Observed
cancers
Excess
cancersa
Attributable
risk %
EAR/
10,000 PY
EAR/10,000 PY compared to general
female population
Observed
cancers
EAR/10,000 PY compared to general
female population
All sites 928 84 9 6 11 1430 4
RT associated
sitesb
226 57 25 4 3 328 0
RT associated sites by latency
5–9 years 66 11 17 3 2 94 1
10–14 years 52 18 35 11 15 78 3
P15 years 39 17 44 23 32 56 4
a Calculated as the number of observed second cancers among the radiotherapy treated women minus the number of second cancers that would have occurred in these
women if they had not been treated with radiotherapy.
b Radiotherapy associated sites: oesophagus, lung, heart/mediastinum, pleura, bones, articular cartilage and connective tissue.
48 Second cancer after radiotherapy in breast cancer patientscrine therapy, and were therefore able to report risk estimates
independent of these other therapies. Radiation treatment tech-
niques and dosages have been nearly constant over the study per-
iod and all patients were treated according to national guidelines.
Additionally, only patients treated on linear accelerators were in-
cluded. Therefore, risk estimates in this study are both reliable
and furthermore reﬂect contemporary standards of radiotherapy.
However, since not all second cancers were histologically veriﬁed,
a minor proportion of tumors may have been misclassiﬁed second-
ary tumors. No information on smoking status, alcohol consump-
tion or BMI was available in this study.
We demonstrated that only second cancers with a close ana-
tomical relation to the former treatment ﬁeld and a priori classiﬁed
as RT-associated had an increased risk 10 or more years after radi-
ation exposure. The observed temporal-pattern for the RT-associ-
ated sites is consistent with the suggestion that radiation-
induced solid tumors have a minimum latency of 5–9 years [22].
In agreement with previous studies we observed an increased
risk of lung cancer among irradiated patients compared with
non-irradiated [3,8,10]. Two additional studies further reported
an increased risk 10 or more years after radiation exposure
[12,23]. It is well known that smoking is strongly related to lung
cancer [24] and it has been suggested that smoking potentiates
the radiation-related risk of lung cancer [25]. Two recent studies
on breast cancer patients demonstrated that the association be-
tween radiotherapy and lung cancer was restricted to ever-smok-
ers [26,27]. The prevalence of female smokers in Denmark has
been high (45% in 1980) but no information on the smoking status
for the cohort was available in this study.
Similar to other studies we found an association between radio-
therapy and soft tissue sarcomas [3,8,10,21]. The majority of the
soft tissue sarcomas among the irradiated women were located
in the thorax or upper arm suggesting a relation to radiotherapy.
There was no signiﬁcantly increased risk of oesophageal cancer
following breast irradiation in this study, but the conﬁdence inter-
val was wide. Data on second oesophageal cancer among breast
cancer patients have been ambiguous where some studies have
shown an association between radiotherapy and oesophageal can-
cer [8,9,12,13,18] while others have not [10,28].
Elevated SIRs of ovarian and endometrial cancer was seen
among radiotherapy-treated, but in line with previous studies
there were no excesses of these sites associated with radiotherapy
[10,19]. It is well established that tamoxifen increases the risk of
endometrial cancer [29–31] and in this study 49% of the irradiated
women had been treated with endocrine therapy.
In this study radiotherapy treated women had an increased risk
of cancer of the CNS. To our knowledge no other studies haveshown this association. For second cancers of the CNS approxi-
mately a third of the patients both among the irradiated and
non-irradiated had a missing histopathology. Some of these CNS
tumors are probably misdiagnosed metatases of breast cancer
which may have led to a slightly overestimated risk. Notably, the
increased incidence was primarily seen 1–4 years after treatment,
suggesting other factors than radiotherapy to be responsible for
the observed excess risk.
We estimated that 9% of the second cancers among the irradi-
ated women were attributable to radiation exposure. This is in
agreement with two recent studies where 6–9% of the second can-
cers among irradiated breast cancer patients were estimated to be
correlated to radiotherapy [8,32]. We further estimated that 25% of
the RT-associated sites could be attributed to radiation exposure.
However, in absolute numbers the risk of developing a radiation-
induced second cancer remains relatively low. When only consid-
ering the RT-associated sites this is equivalent to one radiation-in-
duced second cancer for every 200 women treated with
radiotherapy. This risk has to be placed in a balanced perspective
not only to the known beneﬁts of radiotherapy; but also to other
known late normal-tissue toxicities. In the Early Breast Cancer Tri-
alists’ Collaborative Group’s (EBCTG) meta-analysis of clinical trials
was estimated, that radiotherapy after mastectomy reduces the
absolute 10-year risk of local recurrence by 20% and the absolute
15-year breast cancer mortality by 5.4% compared to surgery only
[3] For women treated with BCS radiotherapy approximately
halves the risk of recurrence and reduces breast cancer death by
around a sixth [5]. Thus, the beneﬁts of radiotherapy by far out-
weighs the risk of developing a second cancer 10 or more years
after treatment.
Radiation-induced cardiac toxicity among breast cancer pa-
tients have been extensively studied over the last 10 years [33–
35]. In EBCTG’s meta-analyses breast-irradiated patients had an
estimated 27% increased risk of cardiac mortality compared to
non-treated patients [3]. In absolute numbers this would roughly
translate into one cardiac death in every 200 women treated with
radiotherapy. In Denmark though, cardiac doses have been low
since the mid 1970s due to treatment techniques that spare the
heart [36]. Hence for Danish patients, treated under DBCG-guide-
lines from 1976 to 2006, the risk of developing a radiation-related
ischaemic heart disease is approximately equivalent to one in
every 400 irradiated women [37]. With the growing clinical aware-
ness towards long-term morbidity after radiotherapy new treat-
ment techniques such as respiratory gating are now entering
clinical practice. On the other hand fairly little clinical attention
has been paid towards radiation-induced second malignancies de-
spite that the risk of developing a radiation-induced second cancer
T. Grantzau et al. / Radiotherapy and Oncology 106 (2013) 42–49 49as shown in this study is of approximately equal magnitude as a
radiation-induced cardiac event. We conclude that breast cancer
patients treated with contemporary radiotherapy techniques have
a small but signiﬁcantly excess risk of second cancers occurring at
sites within or near the treatment ﬁeld. Therefore, future research
is still needed to characterize and understand the dose-risk rela-
tionship surrounding normal tissue for future dose planning and
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